Novartis

News

PTC's Huntington study was positive. Why did its stock fall?

In a potentially pivotal trial, PTC Therapeutics' therapy for Huntington's disease met its primary endpoint, but there are questions about the data.

News

Shreeram Aradhye, Novartis' chief medical officer

Novartis grabs kidney drug developer Regulus in $1.7bn deal

Novartis has grown in renal diseases once again with a $1.7bn deal to buy Regulus and its autosomal dominant polycystic kidney disease (ADPKD) drug.

Market Access

Reuters Europe 2025: Using value propositions to improve acc...

In a Reuters Pharma Europe 2025 fireside chat, NICE Advice Director Brad Grove spoke with Novartis's Matic Meglic about novel pharma payment models.

News

Novartis radioligand therapy (RLT) manufacturing facility

Novartis plans $23bn manufacturing, R&D spend in US

Novartis has announced a massive investment in manufacturing and R&D facilities in the US so it can make "100% of its key medicines" there.

News

Novartis gets FDA nod for second of three IgAN drugs

Novartis has claimed accelerated approval in the US for Vanrafia, one of a trio of drugs it hopes will revolutionise the treatment of IgA nephropathy.

News

Fabhalta is first FDA-approved therapy for rare disease C3G

Novartis' oral complement inhibitor Fabhalta has become the first approved treatment for rare kidney disease C3G as it chases a $3bn sales target.

PTC's Huntington study was positive. Why did its stock fall?

Novartis grabs kidney drug developer Regulus in $1.7bn deal

Reuters Europe 2025: Using value propositions to improve acc...

Novartis plans $23bn manufacturing, R&D spend in US

Novartis gets FDA nod for second of three IgAN drugs

Fabhalta is first FDA-approved therapy for rare disease C3G

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

Novartis

Editor's Picks